MSCL — Satellos Bioscience Income Statement
0.000.00%
Last trade - 00:00- CA$95.20m
- CA$39.25m
- 45
- 26
- 51
- 35
Annual income statement for Satellos Bioscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | fx Final | fx Final | fx Final | fx Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Operating Interest Expense / Income | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1.23 | 12.5 | 8.73 | 11.8 | 23.2 |
| Operating Profit | -1.23 | -12.5 | -8.73 | -11.8 | -23.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.11 | -12.4 | -8.69 | -11.8 | -20.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.11 | -12.4 | -8.7 | -11.8 | -20.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.11 | -12.4 | -8.7 | -11.8 | -20.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.11 | -12.4 | -8.7 | -11.8 | -20.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.144 | -0.189 | -0.203 | -0.133 | -0.153 |